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The outcome of a viral infection reflects the balance between virus virulence and host susceptibility. The clone 13 (Cl13) variant of lymphocytic choriomeningitis virus-a prototype of Old World arenaviruses closely related to Lassa fever virus-elicits in C57BL/6 and BALB/c mice abundant negative immunoregulatory molecules, associated with T-cell exhaustion, negligible T-cell-mediated injury, and high virus titers that persist. Conversely, here we report that in NZB mice, despite the efficient induction of immunoregulatory molecules and high viremia, Cl13 generated a robust cytotoxic T-cell response, resulting in thrombocytopenia, pulmonary endothelial cell loss, vascular leakage, and death within 6-8 d.
These pathogenic events required type I IFN (IFN-I) signaling on nonhematopoietic cells and were completely abrogated by IFN-I receptor blockade. Thus, IFN-I may play a prominent role in hemorrhagic fevers and other acute virus infections associated with severe vascular pathology, and targeting IFN-I or downstream effector molecules may be an effective therapeutic approach.
IFN-alpha | LCMV | platelet loss | immunopathology | lung L assa virus (LASV) is a hemorrhagic fever virus causing platelet malfunction, vascular permeability, and high mortality in a subset of patients (1) . Endemic to West Africa, LASV ranks second in global incidence among hemorrhagic fever viruses, infects hundreds of thousands of individuals annually, and accounts for as many as 15% of hospital admissions in some areas (1, 2) . Although most patients recover after a mild or asymptomatic course, ∼20% develop severe disease, culminating in >20,000 deaths per year. There is no licensed vaccine, and current therapy with ribavirin is limited because of toxicity. Further, the ease of spread and high mortality classifies LASV as a category A pathogen and bioterrorism threat.
The pathogenic mechanisms whereby LASV causes severe disease remain unclear. Studies in vitro with human cells and in vivo in nonhuman primates suggested reduced or delayed induction of type I IFNs (IFN-I), IFN-stimulated genes, and T-cell responses in fatal cases (1, (3) (4) (5) (6) . However, these studies are limited by the small number of animals examined and the lack of direct comparisons between responses in patients with severe vs. mild infections. Thus, it remains unknown how potential innate and adaptive immune dysfunctions might affect vascular integrity and disease severity.
To better understand innate and adaptive immune contributions to virus-induced vascular damage, we performed experiments in susceptible and resistant mice infected with lymphocytic choriomeningitis virus (LCMV). Like LASV, LCMV is an Old World arenavirus and serves as the prototype virus for this subgroup of the Arenaviridae family. Studies on LCMV have provided critical insights into Old World arenavirus virology, immunity, and pathogenesis, and led to the discovery of α-dystroglycan (α-DG), posttranslationally modified by the glycosyltransferase LARGE, as the cognate cellular receptor for both LCMV and LASV (7) (8) (9) (10) .
Here we show that, in susceptible mice, infection with certain variants of LCMV led to induction of a robust cytotoxic T-cell response refractory to negative regulation by inhibitory molecules, platelet loss, up-regulation of MHC class I (MHC-I) molecules by pulmonary endothelial cells, production of inflammatory cytokines and chemoattractants in the lungs, infiltration by activated T cells and inflammatory cells, severe vascular leakage, and death. All these manifestations were suppressed by IFN-I receptor (IFNAR) blockade, suggesting a novel molecular pathway that could be targeted in the treatment of hemorrhagic fevers and other viral conditions associated with lethal vascular injury.
Results and Discussion
The Cl13 Variant of LCMV Causes Lethal Vascular Leakage in NZB Mice.
Two main classes of LCMV isolates have been described, represented by Armstrong (ARM; Cl 53b) and clone 13 (Cl13). Compared with ARM, Cl13 exhibits >100-fold higher affinity for α-DG, more efficiently infects dendritic cells (DCs) and macrophages, replicates at a faster rate in these cells, and reaches higher viremia in mice (11) (12) (13) (14) (15) . Accordingly, i.v. inoculation of adult C57BL/6 or BALB/c mice with ARM induced an acute infection that was cleared within 8-12 d, whereas Cl13 established a persistent infection that lasted >60 d. In contrast, and consistent with an earlier study (16) , infection of NZB mice with Cl13 caused a severe pathological response, indicated by reduced activity, ruffled fur, hunched posture, and labored breathing starting at day 4 postinfection (pi) and death of 100% of the mice Significance Lassa virus is, after dengue virus, the second most common cause of viral hemorrhagic fever. In susceptible individuals, Lassa virus infection is associated with vascular permeability, leading to tissue edema, organ failure, and death. Hemorrhagic fever viruses efficiently infect vascular endothelial cells, but are generally considered noncytopathic. Thus, the mechanism of virus-induced vascular injury remains unclear. Using the lymphocytic choriomeningitis virus variant clone 13, a prototype of Lassa virus, we show here that lethal vascular leakage in susceptible mice was completely prevented by type I IFN receptor blockade. Therefore, approaches that target type I IFNs or effector molecules induced by these cytokines may be considered for the treatment of Lassa fever and other severe hemorrhagic viral illnesses.
(73 of 73) between days 6 and 8 pi (Fig. 1A) . Such manifestations were not observed in ARM-challenged NZB mice, all of which (18 of 18) survived the infection symptomless (Fig. 1A) . Titers of Cl13 in serum were reduced (approximately sixfold) at day 4 pi and increased (∼1.7-fold) at day 6 pi in NZB mice compared with BALB/c controls, whereas no significant differences were noted for ARM (Fig. S1 ). Histological examination of vital organs (lungs, heart, brain, liver, and kidney) on day 6 pi revealed that Cl13 induced pathological alterations primarily in the lungs, which showed marked pneumonitis, alveolar wall thickening, mononuclear cell infiltrate, and edema, consistent with the respiratory distress manifested by moribund mice (Fig.  1B) . In contrast, these histopathological changes were absent in ARM-infected NZB mice (Fig. 1B) , as well as in Cl13-infected C57BL/6 and BALB/c mice (Fig. S2) . Vascular permeability leading to pulmonary edema was confirmed and quantified by the elevated leakage of i.v.-administered Evan's blue in the lungs of NZB mice 5 d after Cl13, but not ARM, infection (Fig. 1C) . As an additional indicator of potential vascular abnormalities, Cl13-infected NZB mice had significantly reduced platelet counts compared with ARM-infected and control mice (Fig. 1D) . Thus, NZB mice infected with Cl13 exhibited an acute disease associated with thrombocytopenia, vascular leakage, and mortality, characteristics typical of severe Lassa fever (LF) and other hemorrhagic fevers.
Mutations in the Virus That Enhance Infection of α-DG-Expressing
Cells and Viral Replication Are Critical for the Pathogenicity of Cl13 in NZB Mice. ARM and Cl13 differ only at three amino acid positions: F260L and N176D in the glycoprotein GP1, and K1079Q in the L polymerase (POL). F260L in GP1 confers enhanced affinity of Cl13 to α-DG and facilitates virus binding and entry into DCs, the cell type that expresses >98% of α-DG located on immune cells (11, 14, 15, 17, 18) ; K1079Q in the L polymerase promotes enhanced (∼100-fold) Cl13 multiplication in DCs (15, 18) ; conversely, N176D in GP1 does not play a significant role on the establishment of infection (14, 15) . To elucidate the role of these amino acid residues in the lethal disease caused by Cl13 in NZB mice, we used four recombinant LCMV (rLCMV) variants ( Fig. 1E ) generated by reverse genetics (19) . The rLCMV S 13 L ARM , expressing POL-1079K (as in ARM) along with GP1-260L and GP1-176D (both as in Cl13), behaved like ARM and induced no pathology in these mice (Fig. 1E ). The rLCMV 176D and S ARM L 13 , both displaying POL-1079Q (as in Cl13) and GP1-260F (as in ARM) but differing in position GP1-176, were slightly more pathogenic than ARM and induced death in only 10-20% of the mice, respectively (Fig. 1E ). In contrast, the rLCMV 260L, expressing POL-1079Q and GP1-260L (both as in Cl13) along with GP1-176N (as in ARM), was as pathogenic as Cl13 and induced death in all mice by day 10 pi (Fig. 1E) . Importantly, the degree of pathogenicity mediated by each of these rLCMVs in NZB mice correlated with the degree of viremia and persistence induced in C57BL/6 mice (14, 15). These results indicate that cell tropism and magnitude of viral load are both critical for the Cl13-induced disease in NZB mice, and residues 260 and 1079 in GP1 and L polymerase, respectively, are key viral genetic determinants of pathogenicity. ) mounted a robust cytotoxic T-cell response to Cl13 that, at day 6 pi, was almost as efficient as in ARM-challenged controls ( Fig.  2A) . Lysis was noted with isologous, but not heterologous, 51 Crlabeled infected target cells (Table S1 ). In addition, increased cytotoxic T lymphocyte (CTL) activity in Cl13-infected NZB mice compared with BALB/c mice correlated with enhanced frequency of virus-specific (H-2 d /LCMV-NP 118-126 -tetramer
+ T cells that also displayed heightened T-cell receptor density and/or affinity, as illustrated by the intensity of MHC/ peptide tetramer staining (Fig. 2B) . These virus-specific NZB T cells exhibited multiple effector functions, indicated by the expression of granzyme B, IFN-γ, or both IFN-γ and TNF-α (Fig.  2C) , an activated phenotype (CD44 hi CD62L low ), and up-regulation of the costimulatory molecule CD137 (4-1BB), known to , ARM (n = 13), or the recombinant viruses S 13 L ARM (n = 10), S ARM L 13 (n = 9), 176D (n = 10), or 260L (n = 13). The Kaplan-Meier survival plot summarizes data from three or four experiments. Significant differences are indicated. *P < 0.05; **P < 0.005; ***P < 0.0005.
promote granzyme B expression. Remarkably, acquisition of inhibitory receptors by virus-specific T cells in Cl13-infected NZB mice was as efficient as in BALB/c mice for PD-1 and TIM-3, and more efficient for LAG-3 (Fig. 2D) . Moreover, serum IL-10 levels were significantly elevated in NZB and BALB/c mice infected with either Cl13 or ARM, with the highest levels observed in Cl13-infected NZB mice (Fig. 2E) . Despite the expression of these negative regulatory molecules, the cytotoxic T cells generated in Cl13-infected NZB mice failed to become functionally exhausted and, instead, robustly contributed to disease progression, because depletion of CD8 + , but not CD4 + , T cells significantly reduced disease and extended survival (Fig. 2F and Fig. S3) . Thus, the anticipated immunosuppressive program was efficiently induced in Cl13-infected NZB mice but did not prevent the development of killer CD8 + T cells, resulting in severe immune-mediated injury.
Cl13 Pathogenicity in NZB Mice Requires Toll-Like Receptor-Independent Production of IFN-α and Is Abrogated by IFNAR Blockade. A cardinal event in the response to most viruses is the early production of high levels of IFN-I. These pleiotropic cytokines are known to ignite a signaling cascade culminating in the expression of multiple costimulatory, proinflammatory, and survival factors necessary for an efficient antiviral response (27) . However, IFN-I has recently been shown to also exert proviral effects, by promoting expression of negative regulatory molecules, leading to T-cell exhaustion and suppression of antiviral responses (24, 25) . We hypothesized that the balance between immunostimulatory and immunosuppressive functions of IFN-I may be altered in some genetically predisposed individuals who, like Cl13-infected NZB mice, develop abnormal antiviral responses associated with severe immunopathology. Serum IFN-α levels and kinetics during the first 6 d pi were similar between Cl13-and ARM-infected NZB mice (Fig. S4) . Remarkably, however, treatment with a blocking antibody to the IFN-I receptor (IFNAR) during the acute phase of the infection, beginning as late as 1 d pi, completely prevented disease manifestations, resulting in 100% (14 of 14) survival of Cl13-infected NZB mice (Fig. 3A and  Fig. S5 ). Treatment efficacy decreased thereafter-i.e., 30% survival when initiated 60 h pi and 0% when initiated 72 h pi (Fig. S5) . After antibody treatment discontinuation, all surviving mice remained free of virus-induced symptoms until they were killed, up to 1 y pi, despite carrying high titers [10 4 -10 5 plaqueforming units (PFU) per mL of serum] of infectious virus. Complete protection from Cl13-mediated acute immunopathology was also observed in congenic Ifnar1 −/− NZB mice lacking the α-chain of IFNAR, whereas all Ifnb −/− NZB mice succumbed by day 6 pi (Fig. 3B) , indicating that IFN-α signaling is sufficient for disease induction.
We next investigated the innate pathways involved in pathogenic IFN-I production. Previous studies in C57BL/6 mice showed that induction of these cytokines by LCMV is mediated by viral RNA engagement of both endosomal Toll-like receptors (TLRs) and cytosolic RNA sensors (RIG-I and MDA5) (28) (29) (30) (31) (32) . We found that congenic NZB mice lacking either expression of TLR3 (Tlr3 −/− ), or signaling by all endosomal TLRs (TLRs 3, 7, and 9) due to the 3d mutation of UNC93B1 (Unc93b1 3d/3d ) (33), succumbed to Cl13 infection unless treated with IFNAR-blocking antibody (Fig. 3C) . These data indicate that the endosomal TLR pathway is not necessary for pathogenic IFN-α production in Cl13-infected NZB mice and that the RIG-I/MDA5-dependent pathway appears to be sufficient for mediating the lethal outcome.
IFNAR Blockade Suppresses the Cytotoxic T-Cell Response and
Prevents Platelet Loss in Cl13-Infected NZB Mice. The beneficial effect of IFNAR blockade in Cl13-infected NZB mice was not ) in spleen of control and infected mice (day 6 pi), assessed by FACS and shown as MFI (average ± SEM; n = 4 mice per group; Student t test). (E) Serum IL-10 levels (day 6 pi) determined by ELISA (average ± SEM; n = 4 mice per group; Student t test). (F) Survival of Cl13-infected NZB mice treated with depleting anti-CD8 or -CD4 antibodies (n = 4 per group). Significant differences are indicated. *P < 0.05; **P < 0.005; ***P < 0.0005.
due to earlier resolution of the infection, because virus titers were significantly increased (∼1,000-fold) 3 d pi in antibodytreated compared with control mice (Fig. 3D) , likely due to the loss of IFN-I antiviral effects. Disease inhibition correlated with complete suppression of the cytotoxic response (Fig. 3E) , consistent with disease reduction in CD8 + T-cell-depleted mice (see above) and reflecting the crucial role of IFN-I in promoting virus-specific T-cell activation, proliferation, and survival (27) . In addition, IFNAR blockade prevented platelet loss occurring in Cl13-infected NZB mice (Fig. 3F) , a finding likely related to the negative effects of IFN-I signaling on megakaryocyte maturation, platelet production, and function (34-37).
IFN-I Signaling on Nonhematopoietic Cells Is Critical for Pathogenicity
in Cl13-Infected NZB Mice. To determine whether IFN-I signaling on hematopoietic cells (particularly CD8 + T cells, antigen-presenting cells, and megakaryocytes) was sufficient to explain the disease-promoting effect, we generated bone marrow chimeras between wild-type (WT) and Ifnar1 −/− NZB mice. Strikingly, unlike WT→WT controls, WT→Ifnar1
−/− chimera, in which bone marrow-derived cells, but not parenchymal cells, can respond to IFN-I, survived Cl13 infection (Fig. 3G) . Thus, the lethal effects of Cl13 in NZB mice can be abrogated by interrupting IFNAR signaling in nonhematopoietic cells. (Fig. 4 A and B) . Similarly, analysis of bronchoalveolar lavage fluid (BALF) showed significant increases in total protein, lactate dehydrogenase, and IgM exudates in the airways of Cl13-infected NZB mice compared with ARM-infected or noninfected controls, and these indicators of vascular hyperpermeability were also corrected by IFNAR blockade (Fig. 4C) . Cl13 infected 62% of lung vascular endothelial cells compared with <1% infected by ARM (Fig. 4D) , consistent with the binding of Cl13 to α-DG, highly expressed by these cells (7, 9, 11, 38) . IFNAR antibody treatment did not inhibit, but rather enhanced, endothelial cell infection, likely due to the absence of antiviral effects mediated by IFN-I signaling (Fig. 4D ). IFNAR blockade also had no effect on the expression of the inhibitory molecule PD-L1, which was strongly up-regulated in Cl13-infected endothelial cells in both treated and nontreated mice (Fig. S6) . IFNAR blockade, however, significantly inhibited MHC-I up-regulation and endothelial cell loss in Cl13-infected NZB mice (Fig. 4E ), which correlated with reduced lung infiltration of multifunctional (IFN-γ + TNF-α + ) CD8 + T cells (Fig. 4F) . Moreover, infiltration of activated macrophages, natural killer (NK) cells, and total leukocytes, significantly elevated in Cl13-infected NZB mice, was also suppressed by IFNAR blockade (Fig. 4G) , as was local production of chemoattractants and cytokines (CCL2, CCL5, and TNF-α) assessed by BALF analysis (Fig. 4H) . In contrast, in nonsusceptible BALB/c mice, Cl13 infected >80% of lung endothelial cells and caused significant up-regulation of MHC-I, but endothelial cell loss was not observed (Fig. S7) , consistent with the paucity of cytotoxic T-cell effectors induced by Cl13 in these mice (Fig. 2) . These data indicate that in susceptible mice # All untreated mice died on day 7 pi and could not be analyzed at day 22. (E) NZB mice were treated or not with IFNARblocking antibody starting 1 d before infection. CTL activity and frequencies of virus-specific and cytokine-producing T cells were assessed on day 6 pi, as specified in Fig. 2 A-C. Data are representative of two independent experiments (n = 3-5 mice per group; Student t test). (F) Blood platelet counts in ARMinfected (n = 5), Cl13-infected (n = 8), and Cl13-infected and treated with anti-IFNAR (n = 8) NZB mice.
# Of the Cl13-infected but untreated mice, two died on day 6 and six on day 7. Data are from two independent experiments (average ± SEM). (G) Survival of Cl13-infected bone marrow chimeras generated between WT and Ifnar1 −/− NZB mice (n = 4 per group). Significant differences are indicated. **P < 0.005; ***P < 0.0005.
IFN-I signaling on infected lung endothelial cells initiates a chain of events-including up-regulation of MHC-I, production of cytokines and chemokines, and recruitment of activated cytotoxic T cells and inflammatory cells-that rapidly lead to endothelial cell loss, vascular permeability, edema, and death in predisposed mice, all of which is suppressed by IFNAR antibody treatment.
Conclusions
Using variants of LCMV and mice with different degrees of susceptibility, we demonstrate that IFN-I critically contributes to virus-induced vascular damage and death-major characteristics of LF and other severe hemorrhagic viral diseases. Highlighting the relevance of both virus and host genetics, lethality in this model correlated with both the efficacy of virus replication in DCs, macrophages, and vascular endothelial cells, and the strength of the host cytotoxic T-cell response, which was IFN-Idependent and resistant to immunoregulatory signals. In addition to NZB mice, preliminary experiments showed similar lethality following Cl13 infection in PL/J and SJL strains of mice. These results suggest that diverse outcomes in susceptible and resistant individuals may reflect differences in virus strain pathogenicity, T-cell response efficiency, and IFN-I-mediated immunoregulation. Although IFN-I has long been thought to protect the host from viral infections due to potent antiviral and immune response-promoting effects, recent studies have implicated these cytokines in harming the host in a number of viral and bacterial infections (24, 25, 39, 40) . The present study provides an additional example of the detrimental contributions of IFN-I during antiviral responses. Defining the molecular mechanisms controlling the switch between beneficial and hurtful effects of IFN-I may therefore have a critical impact on the understanding of antiviral immune responses and susceptibility to immunopathology. Similar to our results with Cl13-infected NZB mice, the pathogenic role of T cells was recently demonstrated in LASV-infected transgenic mice expressing human MHC-I molecules (41) . Whether severe LF in humans is also associated with a pathogenic T-cell response remains unknown. Robust in vitro memory CD4 + T-cell responses to LASV in antibody-seropositive surviving individuals suggested that efficient T-cell immunity develops during nonfatal infections (42) . However, studies that measure the potency of T-cell responses or IFN-I levels in patients with lethal LF have not been reported (3) (4) (5) (6) . We also noted that fatal vascular leakage in Cl13-infected NZB mice correlated with IFN-I-dependent platelet loss. Whether this finding is a cause or a consequence of disease remains to be clarified. In a different virus infection model, platelet loss was also prevented in the absence of IFNAR signaling (34) . Interestingly, lethal disease in Cl13-infected NZB mice required IFN-I signaling in nonhematopoietic cells, as well as efficient infection of endothelial cells, which showed IFN-I-dependent up-regulation of MHC-I and decreased cellularity. Because endothelial cells are also key mediators of inflammatory responses (43) , these events are likely critical for recruitment of immune cells and vascular injury. Like LCMV-Cl13, LASV and other hemorrhagic fever viruses infect endothelial cells, but these viruses are rarely cytopathic, implicating the immune response as the mechanism of vascular leakage (3, 4) . Although blockade of PD-1/PD-L1 engagement has been shown to cause CTL-mediated killing of infected endothelial cells (26) , we show here that in susceptible mice CD8 + T-cell-mediated endothelial damage can occur even when these inhibitory molecules are efficiently up-regulated. Further investigation will be required to clarify why cytotoxic T cells can remain refractory to immunoregulation, how IFN-I signaling contributes to platelet loss and dysfunction, whether IFN-I activates different sets of genes in susceptible vs. resistant mice, and the precise molecular mechanisms involved in IFN-I-dependent vascular pathogenesis. In addition, the relevance of these findings for humans with severe virus-induced hemorrhagic diseases should be assessed, especially the role of IFN-I and its signaling. cytokines in BALF (day 5.5 pi) assessed by ELISA (average ± SEM; n = 3 or 4 mice per group; Student t test). Significant differences are indicated. *P < 0.05; **P < 0.005.
